Unfortunately, and too often, government regulations or other external factors hinder a patient-centered focus on care, including the right to try to save one’s own life. That’s why, as a proud alumnus of the University of Tennessee College of Medicine, I was gratified that the partnership between state Sen. Bo Watson and Beacon Impact was successful in enacting the Right to Try for Individualized Treatments (Right to Try 2.0), a law that protects this fundamental right.
As Sen. Watson points out, for a patient with a rare, debilitating or life-threatening disease, there is no greater fundamental right than being permitted to try to save one’s own life. As a physician, this is precisely where I believe the focus should always be — on the patient and providing more options for treatment.
Right to Try 2.0 is notable for the voluntary nature of the pathway provided for eligible patients with life-threatening or severely debilitating illness to receive an individualized investigational treatment when no other approved therapeutic options for their condition remain. Participation by all parties involved — including physicians, health care facilities, manufacturers and payers — is purely voluntary.
As should be the predicate to any care journey, the process is initiated by a physician and their patient. A physician caring for an eligible patient will attest to the patient’s condition and recommend a potentially beneficial treatment that is based on the patient’s unique genetic profile. Patients, in turn, provide their voluntary informed consent for the treatment.
Health care facilities are eligible to participate in the administration of the identified individualized, investigational therapy only if they are operating in compliance with federal regulations for the protection of human subjects found at 42 U.S.C. Section 289(a) and 45 C.F.R. Part 46. Included among the criteria established by these regulations are standards for diagnostic laboratory facilities, the substance of the patient’s informed consent, and a requisite review of the proposed treatment plan by an institutional review board (IRB). An IRB is an internal committee of physicians, scientists, medical ethicists and others established to protect the rights and welfare of human subjects involved in investigational research.